Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC ...

JMP Securities analyst Jason Butler reiterated a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $7.00.Invest ...

Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...

Edgewise Therapeutics (NASDAQ: EWTX) is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.

Elevance Health Q4 revenues hit $45 billion, driven by premium growth and acquisitions. 2025 EPS guidance is $34.15-$34.85, with a $1.71 dividend declared.

Allbirds (NASDAQ:BIRD – Get Free Report) had its target price lowered by investment analysts at Morgan Stanley from $12.00 to $8.00 in a research note issued to investors on Tuesday,Benzinga reports.